A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology Jg. 151; H. 3; S. 422 - 427
Hauptverfasser:	Monk, Bradley J., Kauderer, James T., Moxley, Katherine M., Bonebrake, Albert J., Dewdney, Summer B., Secord, Angeles Alvarez, Ueland, Frederick R., Johnston, Carolyn M., Aghajanian, Carol
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.12.2018
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical trial Elesclomol Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - pathology Female Humans Hydrazines - pharmacology Hydrazines - therapeutic use Middle Aged Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - pharmacology Paclitaxel - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - pathology Clinical trial Elesclomol Ovarian cancer
ISSN:	0090-8258, 1095-6859, 1095-6859
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!